refractory malignant neoplasm
refractory malignant neoplasm
Explore linked clinical trials. Standard reference: MONDO:003650131 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Financial Distress in Advanced Cancer Patients | Disease Attributes, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, metastatic malignant neoplasm, neoplasm, refractory malignant neoplasm | Active, not recruiting | Not stated | 2026-10-06 | NCT04053517 | |
| Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer | Disease Attributes, Fatigue, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Signs and Symptoms, metastatic malignant neoplasm, neoplasm, refractory malignant neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-22 | NCT02491632 | |
| Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | Disease Attributes, Head and Neck Neoplasms, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Relapse, head and neck cancer, neoplasm, refractory malignant neoplasm | Recruiting | Phase 1 | 2026-09-16 | NCT06096038 | |
| A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, refractory malignant neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-11 | NCT06634589 | |
| IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cancer, neoplasm, refractory malignant neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-01 | NCT05958121 | |
| Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS Tumors | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, central nervous system cancer, central nervous system neoplasm, childhood malignant neoplasm, neoplasm, nervous system disorder, refractory malignant neoplasm | Not yet recruiting | Not applicable | 2026-08-31 | NCT07793994 | |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | DNA Virus Infections, Head and Neck Neoplasms, Herpesviridae infectious disease, Infections, Kaposi's sarcoma, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Adnexal and Skin Appendage, Neoplasms, Connective and Soft Tissue, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Tumor Virus Infections, adenocarcinoma, angiosarcoma, basal cell carcinoma, basal cell neoplasm, carcinoma, cutaneous neuroendocrine carcinoma, epithelial neoplasm, extramammary Paget disease, head and neck squamous cell carcinoma, melanocytic neoplasm, melanoma, metastatic malignant neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, polyomavirus infectious disease, primitive neuroectodermal tumor, refractory malignant neoplasm, sarcoma, sebaceous adenocarcinoma, skin appendage carcinoma, skin disorder, skin neoplasm, skin squamous cell carcinoma, squamous cell carcinoma, squamous cell neoplasm, vascular cancer, viral infectious disease | Recruiting | Phase 1 | 2026-08-12 | NCT05859074 | |
| Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Relapse, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, refractory malignant neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 1 | 2026-07-28 | NCT06347068 | |
| Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | B-cell neoplasm, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, refractory malignant neoplasm | Recruiting | Phase 2 | 2026-07-10 | NCT05852717 | |
| Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, classic Hodgkin lymphoma, neoplasm, refractory malignant neoplasm | Recruiting | Phase 2 | 2026-06-23 | NCT04510636 | |
| A Study of Avutometinib for People With Solid Tumor Cancers | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, low grade glioma, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, neurofibroma, neurofibromatosis type 1, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, plexiform neurofibroma, primitive neuroectodermal tumor, refractory malignant neoplasm | Active, not recruiting | Phase 1 | 2026-06-15 | NCT06104488 | |
| Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes | Disease Attributes, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, metastatic malignant neoplasm, neoplasm, refractory malignant neoplasm | Active, not recruiting | Phase 2 | 2026-06-12 | NCT02286687 | |
| Autologous CAR-T Cells Targeting B7-H3 in PDAC | Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Relapse, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, refractory malignant neoplasm | Recruiting | Phase 1 | 2026-06-08 | NCT06158139 | |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | Adnexal Diseases, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Uveal Neoplasms, cancer, endocrine system disorder, eye disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, ocular cancer, ovarian cancer, ovarian disorder, primitive neuroectodermal tumor, refractory malignant neoplasm, skin disorder, skin neoplasm, uveal disorder, uveal melanoma | Recruiting | Phase 1 / Phase 2 | 2026-05-13 | NCT03686124 | |
| IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cancer, neoplasm, refractory malignant neoplasm | Active, not recruiting | Phase 1 | 2026-04-30 | NCT05359445 | |
| A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm, refractory malignant neoplasm | Not yet recruiting | Not applicable | 2026-04-17 | NCT07535840 | |
| Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Prostatic Cancer, Castration-Resistant, Prostatic Neoplasms, Castration-Resistant, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder, refractory malignant neoplasm | Recruiting | Phase 2 | 2026-04-13 | NCT04337580 | |
| 9-ING-41 in Patients With Advanced Cancers | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Leukemia-Lymphoma, Adult T-Cell, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, T-cell leukemia, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, bone cancer, bone disorder, bone neoplasm, breast disorder, breast neoplasm, cancer, central nervous system malformation, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, glioma, hematologic disorder, hereditary disease, hereditary sensory and autonomic neuropathy, immune system disorder, immunoproliferative disorder, inherited neurodegenerative disorder, intestinal disorder, kidney cancer, kidney disorder, leukemia, lung disorder, lung neoplasm, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, malignant endocrine neoplasm, malignant glioma, malignant pancreatic neoplasm, musculoskeletal system disorder, neoplasm, nervous system disorder, neurodegenerative disease, neuroepithelial neoplasm, neuromuscular disease, pancreas disorder, pancreatic adenocarcinoma, pancreatic neoplasm, peripheral nervous system disorder, polyneuropathy, primitive neuroectodermal tumor, rectal disorder, refractory malignant neoplasm, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, urinary system disorder | Active, not recruiting | Phase 2 | 2026-04-03 | NCT03678883 | |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, neoplasm, primary central nervous system lymphoma, refractory malignant neoplasm | Recruiting | Phase 2 | 2026-03-03 | NCT05681195 | |
| Pembrolizumab, Ibrutinib and Rituximab in PCNSL | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, neoplasm, primary central nervous system lymphoma, refractory malignant neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-02-20 | NCT04421560 | |
| Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, central nervous system cancer, childhood malignant neoplasm, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, nervous system disorder, refractory malignant neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-01-28 | NCT06208657 | |
| Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, clear cell renal carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, rectal disorder, refractory malignant neoplasm, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, urinary system disorder, uterine disorder | Recruiting | Phase 1 | 2025-12-17 | NCT05856981 | |
| Plan Development for Giving Teclistamab in the Outpatient Setting | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, refractory malignant neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 4 | 2025-12-10 | NCT06251076 | |
| A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm, refractory malignant neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-11-20 | NCT06184035 | |
| A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. | neoplasm, refractory malignant neoplasm | Recruiting | Phase 1 | 2025-06-12 | NCT07016997 |